VitaminK2 sensitizes the efficacy of venetoclax in acute myeloid leukemia by targeting the NOXA-MCL-1 pathway. Promising outcomes have been reported in elder patients with acute myeloid leukemia (AML) using combined therapy of venetoclax (VEN) and azacytidine (AZA) in recent years. However, approximately one-third of patients appear to be refractory to this therapy. VitaminK2 (VK2) shows
VitaminK2 in Managing Nocturnal Leg Cramps: A Randomized Clinical Trial Currently, there are no treatments for nocturnal leg cramps (NLCs) that have been proven to be both safe and effective. Seeking safe and effective approaches for managing NLCs is of crucial importance. To determine whether vitaminK2 is better than placebo in managing NLCs. This multicenter, double-blind, placebo-controlled were randomized in a 1:1 ratio to receive vitaminK2 or a placebo for 8 weeks. Patients orally took capsules containing either vitaminK2 (menaquinone 7), 180 μg, or a similar-looking placebo every day for 8 weeks. The study products were custom manufactured to have identical packaging and for the capsules to have matching appearance and identical excipients that shared similar taste and weight
Efficacy of Recombinant Human Parathyroid Hormone 1-34 and VitaminK2 Combination Therapy in Postmenopausal Osteoporosis. This study aimed to assess the efficacy and safety of a combined recombinant human parathyroid hormone 1-34 [rhPTH (1-34)] and vitaminK2 therapy versus vitaminK2 alone in the treatment of postmenopausal osteoporosis. A total of 77 postmenopausal osteoporosis patients were randomly divided into two groups. Patients in one group received vitaminK2 alone, while patients in the other group received a combination of rhPTH (1-34) and vitaminK2. Bone mineral density (BMD), electrolyte levels, pain scores, bone metabolism levels, and adverse drug reactions were compared pre- and post-treatment. Both two treatments improved BMD, blood calcium concentrations, pain scores
VitaminsK2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial. Long COVID (LC) is characterized by persistent symptoms at least 3 months after a SARS-COV-2 infection. LC has been associated with fungal translocation, gut dysfunction, and enhanced systemic inflammation. Currently, there is no approved treatment for this condition. The anti-inflammatory effect of vitaminsK2 and D3 was shown to help attenuate the course of acute COVID-19 infection. This trial aims to investigate the effects of vitaminsK2/D3 on LC symptoms, as well as gut and inflammatory markers, in people with established long COVID. Our hypothesis is that by attenuating systemic inflammation, vitaminsK2/D3 will improve long COVID symptoms. This single-site randomized controlled
VitaminK2 (MK-7) attenuates LPS-induced acute lung injury via inhibiting inflammation, apoptosis, and ferroptosis. Acute lung injury (ALI) is a life-threatening disease that has received considerable critical attention in the field of intensive care. This study aimed to explore the role and mechanism of vitaminK2 (VK2) in ALI. Intraperitoneal injection of 7 mg/kg LPS was used to induce ALI
VitaminK2 Supplementation in Hospitalised COVID-19 Patients: A Randomised Controlled Trial. In observational studies, high levels of desphospho-uncarboxylated matrix gla protein (dp-ucMGP) that result from vitamin K deficiency were consistently associated with poor clinical outcomes during COVID-19. Vitamin K-activated matrix gla protein (MGP) is required to protect against elastic fibre degradation, and a deficiency may contribute to pathology. However, intervention trials assessing the effects of vitamin K supplementation in COVID-19 are lacking. This is a single-centre, phase 2, double-blind, randomised, placebo-controlled trial investigating the effects of vitaminK2 supplementation in 40 hospitalised COVID-19 patients requiring supplemental oxygen. Individuals were randomly assigned
VitaminK2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial Menaquinone-7 (MK-7), also known as vitaminK2, is a cofactor for the carboxylation of proteins involved in the inhibition of arterial calcification and has been suggested to reduce the progression rate of aortic valve calcification (AVC) in patients with aortic stenosis. In a randomized
VitaminK2 supplementation improves impaired glycemic homeostasis and insulin sensitivity for type 2 diabetes through gut microbiome and fecal metabolites. There is insufficient evidence for the ability of vitaminK2 to improve type 2 diabetes mellitus symptoms by regulating gut microbial composition. Herein, we aimed to demonstrate the key role of the gut microbiota in the improvement of impaired glycemic homeostasis and insulin sensitivity by vitaminK2 intervention. We first performed a 6-month RCT on 60 T2DM participants with or without MK-7 (a natural form of vitaminK2) intervention. In addition, we conducted a transplantation of the MK-7-regulated microbiota in diet-induced obesity mice for 4 weeks. 16S rRNA sequencing, fecal metabolomics, and transcriptomics in both study phases
Effect of vitaminK2 in the treatment of nocturnal leg cramps in the older population: Study protocol of a randomized, double-blind, controlled trial. Nocturnal leg cramps (NLCs) are sudden contractions of the leg muscles, usually in the posterior calf muscles at night, affecting sleep quality. Because the precise pathophysiology of NCLs is unclear, different interventions have been proposed . There is conflicting evidence regarding the efficacy of conventional interventions in preventing cramps. Thus, the present study aims to investigate the effects of vitaminK2 for NLCs in a prospective randomized, double-blind, controlled trial. This multicenter, randomized, double-blind, placebo-controlled clinical study will enroll older age (≥65-year-old) with two or more documented episodes of NLCs during 2 weeks
Effect of asciminib and vitaminK2 on Abelson tyrosine-kinase-inhibitor-resistant chronic myelogenous leukemia cells. Abelson (ABL) tyrosine kinase inhibitors (TKIs) are effective against chronic myeloid leukemia (CML); however, many patients develop resistance during ABL TKI therapy. VitaminK2 (VK2) is a crucial fat-soluble vitamin used to activate hepatic coagulation factors and treat
Randomized Controlled Clinical Trial of the Effect of Treatment with VitaminK2 on Vascular Calcification in Hemodialysis Patients (Trevasc-HDK). Vitamin K deficiency among patients on hemodialysis (HD) affects the function of matrix GLA protein (MGP), a potent vitamin K-dependent inhibitor of vascular calcification (VC). We conducted a single-center randomized controlled trial (RCT ) on maintenance HD patients to examine if vitaminK2 supplementation can reduce progression of coronary artery calcification (CAC) over an 18-month study period. Patients were randomized to vitaminK2 group receiving menaquinone-7360 μg 3 times/wk or control group. The primary outcome was CAC scores at the end of the study period. The secondary outcomes were aortic valve calcification (AVC), carotid-femoral
VitaminK2 as a potential therapeutic candidate for the prevention of muscle cramps in hemodialysis patients: A prospective multicenter, randomized, controlled, crossover pilot trial. Muscle cramps occur in 33% to 78% of patients with dialysis. The etiology of muscle cramps is poorly understood, and no clear evidence-based prevention or treatment strategies exist. Improved interventions are urgently needed. The aim of this study was to investigate the effect of vitaminK2 in reducing the frequency and severity of muscle cramps in hemodialysis (HD) patients. This multicenter, randomized, placebo-controlled, crossover clinical trial was conducted from June 2019 to May 2020. Each participant received vitaminK2 (360 µg/d) or placebo for two 4-wk phases, and then crossed to the alternative arm
Fat-Soluble Vitamins in Standard vs. Liposomal Form Enriched with VitaminK2 in Cystic Fibrosis: A Randomized Multi-Center Trial. We aimed to assess a liposomal fat-soluble vitamin formulation containing vitaminK2 with standard treatment in cystic fibrosis (CF). A multi-center randomized controlled trial was carried out in 100 pancreatic-insufficient patients with CF. The liposomal formulation contained vitamin A as retinyl palmitate (2667 IU daily) and beta-carotene (1333 IU), D3 (4000 IU), E (150 IU), K1 (2 mg), and K2 as menaquinone-7 (400 µg). It was compared with the standard vitamin preparations in the closest possible doses (2500 IU, 1428 IU, 4000 IU, 150 IU, 2.14 mg, respectively; no vitaminK2) over 3 months. Forty-two patients finished the trial in the liposomal and 49 in the control
Effect of vitaminK2 administration on depression status in patients with polycystic ovary syndrome: a randomized clinical trial. Patients with Polycystic ovary syndrome (PCOS) are predisposed to the development of several mental comorbidities such as depression. According to several studies, PCOS can be managed by improving insulin sensitivity. The insulin-sensitizing effect of vitamin K has been reported in recent studies. Therefore, in the current trial, we assessed the effect of administrating vitaminK2 (Menaquinone-7) on depression status in women afflicted with PCOS. Eighty-four PCOS women were allocated into the intervention and comparison groups; the intervention group (n = 42) administered 90 µg/day Menaquinone-7, and the comparison group (n = 42) consumed placebo capsules
The impact of vitaminK2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis. A randomized controlled trial. Vascular calcification is one of the most prevalent disorders in pediatric hemodialysis patients that eventually lead to cardiovascular morbidity. VitaminK2 was investigated in adults in previous studies and showed favorable effects on calcification markers. Our aim in this study was to evaluate the efficacy and safety of vitaminK2 and cholecalciferol on the calcification regulators in pediatric patients. A prospective, randomized and controlled trial was conducted on sixty hemodialysis pediatric patients who were divided to four groups; Group 1: administered 100 µg of vitaminK2 (MK-7); Group 2: administered 10 µg
Response by Diederichsen et al to Letter Regarding Article, "VitaminK2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial".
Concurrent Treatment with VitaminK2 and D3 on Spine Fusion in Patients with Osteoporosis-Associated Lumbar Degenerative Disorders. A prospective and nonrandomized concurrent controlled trial. To address the early effects of concurrent treatment with vitaminK2 and vitamin D3 on fusion rates in patients who have undergone spinal surgery. Intervertebral pseudarthrosis has been reported after transforaminal lumbar interbody fusion (TLIF) or posterior lumbar interbody fusion (PLIF), especially in patients with osteopenia or osteoporosis. No study has assessed the early effects of concurrent treatment with vitaminK2 and vitamin D3 on fusion rates. Patients with osteopenia or osteoporosis who underwent TLIF or PLIF in our department were included. Patients in the VK2+VD3 group received vitaminK2
Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without VitaminK2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study Vitamin K antagonists (VKAs), although commonly used to reduce thromboembolic risk in atrial fibrillation, have been incriminated as probable cause of accelerated vascular calcification (VC) in patients on hemodialysis. Functional vitamin K deficiency may further contribute to their susceptibility for VC. We investigated the effect of vitamin K status on VC progression in 132 patients on hemodialysis with atrial fibrillation treated with VKAs or qualifying for anticoagulation. Patients were randomized to VKAs with target INR 2-3, rivaroxaban 10 mg daily, or rivaroxaban 10 mg daily plus vitaminK2 2000 g thrice
Metagenomic Analysis of the Gut Microbiome Reveals Enrichment of Menaquinones (VitaminK2) Pathway in Diabetes Mellitus. Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease with a high prevalence worldwide, especially among overweight and obese populations. T2DM is multifactorial with several genetic and acquired risk factors that lead to insulin resistance. Mounting evidence in the overall taxonomic composition between healthy and T2DM subjects when controlling for differences in diet. However, results showed that T2DM enriched in metabolic pathways involved in menaquinone (vitaminK2) superpathway biosynthesis (PWY-5838) as compared to healthy individuals. Covariance analysis between the bacterial genera and metabolic pathways displaying difference in abundance (analysis